Antiangiogenesis therapy: an update after the first decade

Antiangiogenesis therapy: an update after the first decade

Angiogenesis is a complex biological phenomenon that forms new blood vessels from the pre-existing vasculature. Aberrant angiogenesis has been implicated in a variety of diseases such as cancer, atherosclerosis, arthritis, obesity, pulmonary hypertension, diabetic retinopathy, and age-related macular degeneration. These conditions collectively affect nearly 10% of the global population. Much ef...

Gene therapy: the first decade.

Gene therapy promises to revolutionize medicine by treating the causes of disease rather than the symptoms. We are nearing the end of the first decade of gene therapy, and this article summarizes the approaches taken, results achieved, lessons learned and important recent developments. The early results on the clinical efficacy of gene therapies were disappointing, largely because the available...

Industrial Dynamics-After the First Decade

Antiangiogenesis Therapy for Breast Cancer: An Update and Perspectives from Clinical Trials

The development of new blood vessels is a crucial step in breast cancer growth, progression and dissemination, making it a promising therapeutic target. Breast cancer has a heterogeneous nature and the diversity of responsible angiogenic pathways between different tumors has been studied for many years. Inhibiting different targets in these pathways has been under investigation in preclinical a...

Gene therapy for antiangiogenesis.

Angiogenesis inhibitors have evolved as a new diverse class of compounds that can be used to block tumor growth (1,2). The inhibitors, which may be natural or synthetic, include protease inhibitors (i.e., tissue inhibitors of matrix metalloproteinases), tyrosine kinase inhibitors, chemokines, interleukins, and proteolytic fragments of diverse molecules (i.e., endostatin, vasostatin, canstatin, ...